---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-003346"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2026-05-13T11:31:16+00:00"
generated_at: "2026-05-13T11:38:01.542316+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arbutus Q1 net income $169.7M ($0.88/share) on $179.1M revenue from Moderna settlement

## Summary
- Revenue $179.1M up from $1.8M YoY; $178.7M license revenue from Genevant related to Moderna settlement.
- Net income $169.7M vs net loss $24.5M in Q1 2025; diluted EPS $0.87.
- Moderna settlement: $950M noncontingent payment due July 2026; Arbutus expects ~$178.7M.
- Cash, equivalents and marketable securities $95.2M as of March 31, 2026.
- FDA granted Fast Track designation for imdusiran for chronic hepatitis B.

## SEC filing metadata
- accession: 0001171843-26-003346
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2026-05-13T11:31:16+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184326003346/0001171843-26-003346-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184326003346/f8k_051226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-003346
- JSON: https://secwatch.observer/filing/0001171843-26-003346.json
- Plain text: https://secwatch.observer/filing/0001171843-26-003346.txt

## Key facts
- Earnings Releases
  Arbutus Biopharma Corp reported first quarter ended March 31, 2026 results: revenue $179.1 million, net income $169.7 million, EPS income of $0.88 per basic and $0.87 per diluted common share.
  - Period: first quarter ended March 31, 2026
  - Revenue: $179.1 million
  - Net income: $169.7 million
  - EPS: income of $0.88 per basic and $0.87 per diluted common share
  - Result: reported results
  source text: Revenue Total revenue was $179.1 million for the quarter ended March 31, 2026, compared to $1.8 million for the same period in 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447028/000117184326003346/0001171843-26-003346-index.htm
- Earnings Releases
  Arbutus Biopharma Corp reported quarter ended March 31, 2026 results: net income For the quarter ended March 31, 2026, the Company’s net income was $169.7 million, or income of $0.88 per basic and $0.8, EPS income of $0.88 per basic and $0.87 per diluted common share.
  - Period: quarter ended March 31, 2026
  - Net income: For the quarter ended March 31, 2026, the Company’s net income was $169.7 million, or income of $0.88 per basic and $0.8
  - EPS: income of $0.88 per basic and $0.87 per diluted common share
  - Result: reported results
  source text: Total revenue was $179.1 million for the quarter ended March 31, 2026, compared to $1.8 million for the same period in 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447028/000117184326003346/0001171843-26-003346-index.htm
- Earnings Releases
  Arbutus Biopharma Corp reported quarter ended March 31, 2026 results: net income For the quarter ended March 31, 2026, the Company’s net income was $169.7 million, or income of $0.88 per basic and $0.8, EPS income of $0.88 per basic and $0.87 per diluted common share.
  - Period: quarter ended March 31, 2026
  - Net income: For the quarter ended March 31, 2026, the Company’s net income was $169.7 million, or income of $0.88 per basic and $0.8
  - EPS: income of $0.88 per basic and $0.87 per diluted common share
  - Result: reported results
  source text: For the quarter ended March 31, 2026, the Company’s net income was $169.7 million, or income of $0.88 per basic and $0.87 per diluted common share, as compared to a net loss of $24.5 million, or a loss of $0.13 per basic and diluted common share, for the quarter ended March 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447028/000117184326003346/0001171843-26-003346-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.